Biopharma firm Adlai Nortye reports first-half GAAP loss of $0.04 per share on $13.06M revenue, with cash reserves surging to $231.9 million.
Adlai Nortye reported a GAAP loss of $0.04 per share for the first half of the year, alongside revenue of $13.06 million. The results reflect ongoing investment in clinical development and operational expansion, though revenue fell short of analyst expectations for the period.
Cash and cash equivalents, including short-term investments, rose sharply to $231.9 million as of June 30, 2026, up from $8.1 million at the end of 2025. The increase follows recent financing activities, bolstering the company’s liquidity position amid pipeline advancement.
Shares showed muted movement in pre-market trading, as investors weighed the wider loss against improved cash reserves and long-term growth prospects.